Integral BioSystems and Patents Etcetera Jointly Offer Integrated IP-Drug Development Strategies
Publish Date: 09/20/2012
Two Boston area firms, contract research organization (CRO) Integral BioSystems, LLC and intellectual property (IP) law firm Patents Etcetera have joined forces in offering drug development services that start with an IP strategy review.
Instead of investing dollars and time in a lengthy approval process for a new chemical entity (NCE), many pharmaceutical companies are seeking to reduce risks and costs by finding new uses for existing drugs. Companies that take this approach fit naturally within the risk reduction model because they start with approved compounds with established history of use in humans. This approach to drug development, using repurposed, already-approved compounds, can make it possible for new drug formulations to enter the clinical development phase more rapidly and at much lower cost than when NCEs are used.
Companies taking this approach to "repurpose" drugs use one or a combination of the following strategies: (a) reformulating to “improve" efficacy, (b) discovery of new targets for old drugs, (c) reformatting an old drug with an established mechanism of action for another indication or (d) repurposing existing drugs to identify novel uses. While these approaches offer easier regulatory approval paths compared to the lengthy approval process for a New Drug Application (NDA) for a new chemical entity, new challenges have emerged in terms of gaining patent protection and product exclusivity for the new "repurposed" products.
Patent Attorney Dave Karasic (DBA Patents Etcetera) advises drug development companies about the patentability of their drug and its proposed clinical indication, suggesting ways to gain new patent protection for off-patent and/or repurposed drugs. The strategies and approaches are developed in collaboration with drug delivery/ drug development experts at Integral BioSystems.
Integral BioSystems excels in the conceptualization and design of innovative drug delivery solutions for drug candidates that are unstable, intrinsically tissue impermeable, or incompatible with physiological fluids. With extensive experience developing sustained release systems incorporating microspheres, nanospheres, liposomes, depots, etc., Integral BioSystems specializes in the removing “roadblocks” preventing companies from leveraging the full potential of their proposed drug products.
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.